The synthesis of [3H]L-734,217, an orally active fibrinogen receptor antagonist

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 38, Issue 6, 1996, Pages 533-540

  Hamill, Terence G ^a   Duggan, Mark E ^b   Hartman, George D ^b   Hoffman, William F ^b   Perkins, Jim J ^b   Burns, H Donald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WP44C 2   (United States)

Author keywords

catalytic tritiation; Fibrinogen receptor antagonist; L 734,217; tritium NMR

Indexed keywords

NUCLEAR MAGNETIC RESONANCE; ORGANIC SOLVENTS; PLATINUM COMPOUNDS;

% REDUCTIONS; BASIC HYDROLYSIS; CATALYTIC TRITIATION; FIBRINOGEN RECEPTOR ANTAGONIST; L-734,217; ORALLY ACTIVE; RECEPTOR ANTAGONISTS; STEP SEQUENCES; TRITIATION; TRITIUM NMR;

TRITIUM;

3 [2 (PIPERIDIN 4 YL)ETHYL] 2 PIPERIDONE 1 ACETYL 3 METHYL BETA ALANINE H 3; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; L 734217; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG USE; ISOTOPE LABELING; PROTON TRANSPORT; THROMBOGENESIS; THROMBOSIS;

EID: 0029892595     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1344(199606)38:6<533::AID-JLCR865>3.0.CO;2-R     Document Type: Article

References (13)

1. Stein B., Fuster V., Israel D.H., Cohen M., Badimon L., Badimon J.J. and Chesebro J.H.-J. Am. Coll. Cardiol. 14: 813 (1989).
2. Phillips D.R., Charo I.F., Parise L.V. and Fitzgerald L.A.-Blood, 71: 831 (1988).
3. Zablocki J.A., Nicholson, N.S., Feigen, L.P.-Exp. Opin. Invest. Drugs, 3: 437 (1994).
4. Hanson S.R., Pareti F.I., Ruggeri Z.M., Marzec U.M., Kunicki T.J., Montgomery R.R., Zimmerman T.S. and Harker L.A.-J. Clin. Invest. 81: 149 (1988).
5. Yasuda T., Gold H.K., Fallon J.T., Leinbach R.C., Guerrero J.L., Scudder L.E., Kanke M., Shealy D., Ross M.J., Collen D. and Coller B.S.-J. Clin. Invest. 81: 1284 (1988), 81.
6. Jackson S., DeGrado W., Dwivedi A., Parthasarathy A., Higley A., Krywko J., Rockwell A., Markwalder J., Wells G., Wexler R., Mousa S. and Harlow R.-J. Am. Chem. Soc. 116: 3220 (1994).
7. Ali F.E., Bennett D.B., Calvo R.R., Elliott J.D., Hwang S-M., Ku T.W., Lago M.A., Nichols A.J., Romoff T.T., Shah D.H., Vasko J.A., Wong A.S., Yellin T.O., Yuan C-K. and Samanen J.M.-J. Med. Chem. 37: 769 (1994).
8. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J., Zhang G., Chang C.T.C. and Gould R.J.-J. Med. Chem. 35: 4640 (1992).
9. Duggan M.E., Naylor-Olsen A.M., Perkins J.J., Anderson P.S., Chang C.T.C., Cook J.J., Gould R.J., Ihle N.C., Hartman G.D., Lynch J.J, Lynch R.J., Manno P.D., Schaffer L.W. and Smith R.L.-J. Med. Chem. 38: 3332 (1995).
10. Evans E.A.-Tritium and its Compounds, Van Nostrand, New York (1966).
11. McNamara J.M, Leazer J.L., Bhupathy M., Amato J.S., Reamer R.A., Reider P.J. and Grabowski E.J.J.-J. Org. Chem. 54: 3718 (1989).
12. Johnstone R.A., Wilby A.H. and Entwistle I.D.-Chem. Rev. 85:129 (1985)
13. 1H NMR spectrum had a δ4.93 (vinyl proton) and a δ2.38 (vinyl methyl) signal in addition to the peaks due to 7. This sample was hydrolyzed to produce 9 (along with unlabelled 1).